StreetInsider.com News Articles

Compass Pathways launches first U.S. awareness day for treatment-resistant depression

Wed, 14 Oct 2026 06:30:36 -0400

Compass Pathways plc (Nasdaq: CMPS) has announced the first U.S. Treatment-Resistant Depression (TRD) Awareness Day, a campaign backed by the National Alliance on Mental Illness (NAMI), Mental Health America (MHA), and the Depression and Bipolar Support Alliance (DBSA).

TRD is estimated to affect approximately 4 million people in the U.S. and is defined as an inadequate response to two or more approved antidepressant treatments. Fewer than 5% of those with TRD are currently on a TRD-indicated treatment, according to data cited in the press release.

A survey commissioned by Compass Pathways found that nearly 95% of people living with TRD describe themselves

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

Wed, 14 Oct 2026 06:30:00 -0400

First-ever Treatment-Resistant Depression (TRD) Awareness Day establishes dedicated moment to recognize and raise awareness of the condition’s profound impact on patients and their loved ones
Survey data in a new report highlighting the significant burden of TRD on patients and caregivers to be released in a future communication

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

Wed, 14 Oct 2026 06:30:00 -0400

First-ever Treatment-Resistant Depression (TRD) Awareness Day establishes dedicated moment to recognize and raise awareness of the condition’s profound impact on patients and their loved ones
Survey data in a new report highlighting the significant burden of TRD on patients and caregivers to be released in a future communication

2026 Patient Innovators Awards Winners Announced at Courier Health's Annual Summit

Tue, 13 Oct 2026 09:00:00 -0400

Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience

NEW YORK, Oct. 13, 2026 /PRNewswire/ -- Courier Health, the leading technology company for managing patient experiences, today announced the winners of the second annual Patient Innovators Awards, which recognize the biopharma teams and leaders going above and

2026 Patient Innovators Awards Winners Announced at Courier Health's Annual Summit

Tue, 13 Oct 2026 09:00:00 -0400

Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience

Increasing unusual put option volume: EWG FEZ MTUM TWST CMPS IYR ABCL PENG BXSL NTSK ARKG

Wed, 07 Oct 2026 10:21:25 -0400

Increasing unusual put option volume: EWG FEZ MTUM TWST CMPS IYR ABCL PENG BXSL NTSK ARKG

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 06:30:00 -0400

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 06:30:00 -0400

Compass Pathways Appoints Kelley Boucher as Chief People Officer

Wed, 30 Sep 2026 06:30:00 -0400

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval,

Compass Pathways Appoints Kelley Boucher as Chief People Officer

Wed, 30 Sep 2026 06:30:00 -0400

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval,

Over $3.6M Raised to Build a More Connected Future of Mental Health at 32nd One Mind Music Festival Featuring The Fray

Wed, 23 Sep 2026 15:11:00 -0400

With over 500 attendees, the event spotlighted cutting-edge science and innovation, celebrated exceptional wine and food, and welcomed beloved band, The Fray

RUTHERFORD, Calif.--(BUSINESS WIRE)-- On Saturday, September 19, 2026, leaders in science, philanthropy, and business, community members, and advocates gathered at the Staglin Family Vineyard in Napa Valley for the 32nd annual One Mind Music Festival, presented by Bank of America and Bristol Myers Squibb. The event welcomed more than 500 guests and raised over $3.6M to advance mental health research and discovery.

This press release features multimedia. View the full release here:

Over $3.6M Raised to Build a More Connected Future of Mental Health at 32nd One Mind Music Festival Featuring The Fray

Wed, 23 Sep 2026 15:11:00 -0400

With over 500 attendees, the event spotlighted cutting-edge science and innovation, celebrated exceptional wine and food, and welcomed beloved band, The Fray

This press release features multimedia. View the full release here:

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

Wed, 16 Sep 2026 06:30:00 -0400

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET.

A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ

A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

Wed, 16 Sep 2026 06:30:00 -0400

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET.

A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ

A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the

Oppenheimer sees positive outlook for psychedelics after FDA hearing

Wed, 16 Sep 2026 05:31:27 -0400

Investing.com -- Oppenheimer said Wednesday that a recent FDA public hearing on psychedelics medicine created a supportive regulatory environment for potential approvals and market access. The firm maintains its positive stance on CMPS and DFTX.

The hearing brought together physicians, industry representatives, and advocates who emphasized the urgent need to address mental health treatment gaps while establishing strict safety and risk management protocols.

Oppenheimer's conversations with biotechnology companies and investors after the hearing indicated growing confidence in the FDA's openness to psychedelics treatments, though the agency is expected to maintain appropriate safety standards.

The firm expects near-term commercial launches of CMPS's COMP360, which

Oppenheimer sees positive outlook for psychedelics after FDA hearing

Wed, 16 Sep 2026 05:31:27 -0400

The firm expects near-term commercial launches of CMPS's COMP360, which

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Tue, 15 Sep 2026 06:30:00 -0400

New U.S. healthcare provider (HCP) disease education initiative, Change the Tune in TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD)
TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Tue, 15 Sep 2026 06:30:00 -0400

New U.S. healthcare provider (HCP) disease education initiative, Change the Tune in TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD)
TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode

Strata Mental Health gets Compass Pathways grant for COMP360 training

Fri, 11 Sep 2026 16:10:15 -0400

Strata Mental Health Solutions, an Atlanta-based clinical training firm, has received one of five U.S. healthcare provider training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop provider training programs for COMP360, Compass Pathways' investigational psilocybin treatment.

The grant is intended to support provider training if COMP360 receives regulatory approval. Compass Pathways has reported positive results from two Phase 3 trials of COMP360. The company expects its New Drug Application submission to be complete in the fourth quarter of 2026 under a rolling submission and FDA review pathway, with a commercial launch anticipated in the first half of 2027.

Under the grant,

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Fri, 11 Sep 2026 16:10:00 -0400

Strata’s implementation platform includes provider training, certification, site readiness, and ongoing clinical support; its founders worked with Compass on the COMP360 training program for clinicians, who supported and monitored participants in Compass' clinical trials.

ATLANTA--(BUSINESS WIRE)-- Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass’ investigational psilocybin treatment, if approved. Strata’s founders worked with Compass on the development of

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Fri, 11 Sep 2026 16:10:00 -0400

Fluence to develop psilocybin provider training for Compass Pathways

Thu, 10 Sep 2026 08:01:48 -0400

Fluence, a professional education company focused on psychedelic therapy, has been selected by Compass Pathways plc (Nasdaq: CMPS) to develop a clinician certificate program tied to COMP360, Compass Pathways' investigational synthetic psilocybin treatment currently being evaluated for treatment-resistant depression.

The selection was made through a competitive process, according to a press release from Fluence. The resulting program, called the Post-Approval COMP360 Psilocybin Certificate Program, is designed to prepare healthcare providers to support patients receiving COMP360 treatment, contingent on U.S. Food and Drug Administration approval.

The program will be structured across three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification. The

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Thu, 10 Sep 2026 08:00:00 -0400

New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360 psilocybin treatment, if approved by the

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Thu, 10 Sep 2026 08:00:00 -0400

New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Thu, 10 Sep 2026 06:35:00 -0400

Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants
Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to